CN106443016B - 用于检测多特异性结合物的结合搭档的方法 - Google Patents
用于检测多特异性结合物的结合搭档的方法 Download PDFInfo
- Publication number
- CN106443016B CN106443016B CN201610880999.2A CN201610880999A CN106443016B CN 106443016 B CN106443016 B CN 106443016B CN 201610880999 A CN201610880999 A CN 201610880999A CN 106443016 B CN106443016 B CN 106443016B
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- sample
- specificity
- binding specificity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 126
- 239000000427 antigen Substances 0.000 claims abstract description 360
- 102000036639 antigens Human genes 0.000 claims abstract description 357
- 108091007433 antigens Proteins 0.000 claims abstract description 357
- 230000027455 binding Effects 0.000 claims abstract description 275
- 239000007790 solid phase Substances 0.000 claims abstract description 62
- 239000011230 binding agent Substances 0.000 claims description 50
- 238000001514 detection method Methods 0.000 claims description 41
- 108010090804 Streptavidin Proteins 0.000 claims description 40
- 239000000700 radioactive tracer Substances 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 239000011324 bead Substances 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 238000000338 in vitro Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000003018 immunoassay Methods 0.000 claims description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 235000018977 lysine Nutrition 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 230000021615 conjugation Effects 0.000 claims description 12
- 230000009870 specific binding Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 8
- -1 carboxyl- Chemical group 0.000 claims description 8
- 230000005298 paramagnetic effect Effects 0.000 claims description 7
- 230000003302 anti-idiotype Effects 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 5
- 229920002684 Sepharose Polymers 0.000 claims description 4
- 239000012491 analyte Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 125000000837 carbohydrate group Chemical group 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 20
- 230000001745 anti-biotin effect Effects 0.000 claims 1
- 150000002669 lysines Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000523 sample Substances 0.000 description 142
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 63
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 63
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 43
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 43
- 102100034608 Angiopoietin-2 Human genes 0.000 description 32
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 32
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 32
- 238000005406 washing Methods 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 15
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 15
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 15
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 15
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 15
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 230000000779 depleting effect Effects 0.000 description 9
- 239000006148 magnetic separator Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 150000005846 sugar alcohols Chemical group 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000012070 reactive reagent Substances 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003318 immunodepletion Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000710779 Trina Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005553 polystyrene-acrylate Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002094 self assembled monolayer Substances 0.000 description 1
- 239000013545 self-assembled monolayer Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 102000005963 steroid binding proteins Human genes 0.000 description 1
- 108020003178 steroid binding proteins Proteins 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12153457 | 2012-02-01 | ||
| EP12153457.2 | 2012-02-01 | ||
| EP12182505 | 2012-08-31 | ||
| EP12182505.3 | 2012-08-31 | ||
| CN201380007278.5A CN104105966B (zh) | 2012-02-01 | 2013-01-29 | 用于检测多特异性结合物的结合搭档的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380007278.5A Division CN104105966B (zh) | 2012-02-01 | 2013-01-29 | 用于检测多特异性结合物的结合搭档的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106443016A CN106443016A (zh) | 2017-02-22 |
| CN106443016B true CN106443016B (zh) | 2019-08-13 |
Family
ID=47624068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610880999.2A Active CN106443016B (zh) | 2012-02-01 | 2013-01-29 | 用于检测多特异性结合物的结合搭档的方法 |
| CN201380007278.5A Active CN104105966B (zh) | 2012-02-01 | 2013-01-29 | 用于检测多特异性结合物的结合搭档的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380007278.5A Active CN104105966B (zh) | 2012-02-01 | 2013-01-29 | 用于检测多特异性结合物的结合搭档的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9945869B2 (enExample) |
| EP (1) | EP2810074B1 (enExample) |
| JP (3) | JP2015507193A (enExample) |
| KR (1) | KR20140128314A (enExample) |
| CN (2) | CN106443016B (enExample) |
| BR (1) | BR112014017630A8 (enExample) |
| CA (1) | CA2859268A1 (enExample) |
| MX (1) | MX349661B (enExample) |
| RU (1) | RU2620563C2 (enExample) |
| WO (1) | WO2013113663A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013113663A1 (en) | 2012-02-01 | 2013-08-08 | F. Hoffmann-La Roche Ag | Method for the detection of a binding partner of a multispecific binder |
| BR112015000665A2 (pt) | 2012-07-13 | 2017-06-27 | Hoffmann La Roche | método para a determinação da quantidade de um anticorpo |
| WO2015067547A1 (en) | 2013-11-05 | 2015-05-14 | Roche Diagnostics Gmbh | A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto |
| CN104109197B (zh) * | 2013-11-13 | 2017-05-10 | 叶森 | 一种双识别抗体片段的制备方法及其应用 |
| SI3356411T1 (sl) | 2015-10-02 | 2021-09-30 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, specifična za PD1 in TIM3 |
| WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
| EP4421088A3 (en) * | 2017-02-06 | 2024-12-04 | Uit de Krempe IP B.V. | C-peptide's interaction with elastin receptor, a blueprint for understanding vascular disease |
| MX2019011770A (es) | 2017-04-03 | 2020-01-09 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15. |
| DK3606955T3 (da) | 2017-04-05 | 2025-01-13 | Hoffmann La Roche | Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3 |
| JP7370322B2 (ja) | 2018-06-04 | 2023-10-27 | 中外製薬株式会社 | 複合体を検出する方法 |
| CN119470884A (zh) * | 2019-05-13 | 2025-02-18 | 豪夫迈·罗氏有限公司 | 抑制干扰的药代动力学免疫测定 |
| WO2022065052A1 (ja) * | 2020-09-24 | 2022-03-31 | 株式会社Ｊｖｃケンウッド | 捕捉用抗体、固相担体、検出用抗体、固相担体粒子、並びに検出対象物質の測定キット及び測定方法 |
| CN117805397A (zh) * | 2024-02-29 | 2024-04-02 | 军科正源（北京）药物研究有限责任公司 | 检测游离vegf的方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11352129A (ja) * | 1998-06-04 | 1999-12-24 | Mizuho Medeii:Kk | 検出装置及び検出方法 |
| JP2001524674A (ja) * | 1997-11-21 | 2001-12-04 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 置換アッセイにおける改良又は置換アッセイに関する改良 |
| CN101268372A (zh) * | 2005-07-21 | 2008-09-17 | 根马布股份公司 | 与fc受体结合的抗体药物的药效测定 |
| JP2011523853A (ja) * | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219730A (en) | 1982-09-28 | 1993-06-15 | New York University | Idiotype-anti-idiotype immunoassay |
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| EP0170302A1 (fr) | 1984-06-27 | 1986-02-05 | l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire | Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| WO1987002778A1 (en) | 1985-10-22 | 1987-05-07 | Cooper-Lipotech | Solid-phase liposome immunoassay system |
| ATE180057T1 (de) | 1988-11-03 | 1999-05-15 | Igen Int Inc | Elektrochemilumineszente testverfahren |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| JPH07509128A (ja) | 1992-07-13 | 1995-10-12 | バイオネブラスカ・インコーポレーテッド | 組換型ポリペプチドの修飾方法 |
| JPH097096A (ja) | 1995-06-20 | 1997-01-10 | Alpine Electron Inc | 緊急車両接近時の報知方法 |
| JPH0975096A (ja) * | 1995-09-14 | 1997-03-25 | Snow Brand Milk Prod Co Ltd | ラクトフェリンの測定法 |
| US6753189B1 (en) * | 1998-06-04 | 2004-06-22 | Mizuho Medy Co., Ltd. | Detection apparatus and method for the same |
| ATE315789T1 (de) * | 1999-11-16 | 2006-02-15 | Genentech Inc | Elisa für vegf |
| GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| US7341837B2 (en) * | 2003-09-02 | 2008-03-11 | Lawton Robert L | Soluble analyte detection and amplification |
| CA2597996A1 (en) | 2005-03-08 | 2006-09-14 | Tanox, Inc. | Methods for determining the bivalency of protein and antibody therapeutics |
| US7494776B2 (en) | 2005-07-07 | 2009-02-24 | Beckman Coulter, Inc. | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands |
| US9580506B2 (en) | 2005-07-21 | 2017-02-28 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
| SI2069798T1 (sl) * | 2006-10-04 | 2014-07-31 | Genentech, Inc. | ELISA za VEGF |
| EP1917854A1 (en) | 2006-11-06 | 2008-05-07 | F. Hoffmann-La Roche Ag | Method for producing anti idiotypic antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP2344884B1 (en) * | 2008-10-07 | 2013-07-31 | Gyros Patent Ab | Semi-sequential assay for detection of an analyte in a sample |
| CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| PE20120540A1 (es) | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| SG2014014823A (en) * | 2009-10-19 | 2014-07-30 | Hoffmann La Roche | Non-cross-reactive anti igg antibodies |
| CN102207504A (zh) * | 2011-03-23 | 2011-10-05 | 北京华创远航科技有限公司 | 一种酶联检测试剂盒及其制备方法 |
| CN104040350B (zh) | 2011-12-19 | 2016-05-18 | 弗·哈夫曼-拉罗切有限公司 | 用于检测多特异性结合物的游离结合搭档的方法 |
| WO2013113663A1 (en) | 2012-02-01 | 2013-08-08 | F. Hoffmann-La Roche Ag | Method for the detection of a binding partner of a multispecific binder |
| US20130231462A1 (en) * | 2012-02-27 | 2013-09-05 | Bio-Rad Laboratories, Inc. | Anti-immune complex antibodies |
| BR112015000665A2 (pt) | 2012-07-13 | 2017-06-27 | Hoffmann La Roche | método para a determinação da quantidade de um anticorpo |
-
2013
- 2013-01-29 WO PCT/EP2013/051604 patent/WO2013113663A1/en not_active Ceased
- 2013-01-29 CN CN201610880999.2A patent/CN106443016B/zh active Active
- 2013-01-29 CA CA2859268A patent/CA2859268A1/en not_active Abandoned
- 2013-01-29 RU RU2014133701A patent/RU2620563C2/ru not_active IP Right Cessation
- 2013-01-29 CN CN201380007278.5A patent/CN104105966B/zh active Active
- 2013-01-29 KR KR1020147021674A patent/KR20140128314A/ko not_active Ceased
- 2013-01-29 EP EP13701628.3A patent/EP2810074B1/en active Active
- 2013-01-29 BR BR112014017630A patent/BR112014017630A8/pt not_active IP Right Cessation
- 2013-01-29 MX MX2014008762A patent/MX349661B/es active IP Right Grant
- 2013-01-29 JP JP2014555164A patent/JP2015507193A/ja active Pending
-
2014
- 2014-08-01 US US14/449,437 patent/US9945869B2/en active Active
-
2017
- 2017-08-29 JP JP2017163827A patent/JP6502441B2/ja active Active
-
2018
- 2018-03-16 US US15/923,773 patent/US10761097B2/en active Active
-
2019
- 2019-03-20 JP JP2019052527A patent/JP6678792B2/ja active Active
-
2020
- 2020-07-31 US US16/945,730 patent/US20210055304A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001524674A (ja) * | 1997-11-21 | 2001-12-04 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 置換アッセイにおける改良又は置換アッセイに関する改良 |
| JPH11352129A (ja) * | 1998-06-04 | 1999-12-24 | Mizuho Medeii:Kk | 検出装置及び検出方法 |
| CN101268372A (zh) * | 2005-07-21 | 2008-09-17 | 根马布股份公司 | 与fc受体结合的抗体药物的药效测定 |
| JP2011523853A (ja) * | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
Non-Patent Citations (2)
| Title |
|---|
| Characterisation of a humanised bispecific monoclonal antibody for cancer therapy;A. Bruynck et al.;《Br. J. Cancer》;19930301;第67卷(第3期);436-440 |
| Rapid Detection of Hepatitis B Virus Surface Antigen by an Agglutination Assay Mediated by a Bispecific Diabody against Both Human Erythrocytes and Hepatitis B Virus Surface Antigen;Yu-Ping Chen et al.;《Clinical and Vaccine Immunology》;20070418;第14卷(第6期);720-725 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104105966B (zh) | 2016-10-26 |
| CN106443016A (zh) | 2017-02-22 |
| BR112014017630A2 (enExample) | 2017-06-20 |
| MX2014008762A (es) | 2014-08-27 |
| HK1202921A1 (en) | 2015-10-09 |
| BR112014017630A8 (pt) | 2017-07-11 |
| KR20140128314A (ko) | 2014-11-05 |
| WO2013113663A1 (en) | 2013-08-08 |
| RU2014133701A (ru) | 2016-03-27 |
| CA2859268A1 (en) | 2013-08-08 |
| MX349661B (es) | 2017-08-08 |
| CN104105966A (zh) | 2014-10-15 |
| US20210055304A1 (en) | 2021-02-25 |
| JP6678792B2 (ja) | 2020-04-08 |
| JP2017223710A (ja) | 2017-12-21 |
| JP6502441B2 (ja) | 2019-04-17 |
| JP2015507193A (ja) | 2015-03-05 |
| RU2620563C2 (ru) | 2017-05-26 |
| US20140342382A1 (en) | 2014-11-20 |
| US10761097B2 (en) | 2020-09-01 |
| JP2019113564A (ja) | 2019-07-11 |
| US9945869B2 (en) | 2018-04-17 |
| EP2810074B1 (en) | 2017-08-23 |
| EP2810074A1 (en) | 2014-12-10 |
| US20180328942A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106443016B (zh) | 用于检测多特异性结合物的结合搭档的方法 | |
| CN104040350B (zh) | 用于检测多特异性结合物的游离结合搭档的方法 | |
| CN104471397B (zh) | 用于检测多特异性结合物的方法 | |
| CN107076761B (zh) | 用于测定针对效应子功能抑制的人或人源化药物抗体的抗药物抗体的方法 | |
| CN113811770A (zh) | 抑制干扰的药代动力学免疫测定 | |
| HK1230718B (zh) | 用於检测多特异性结合物的结合搭档的方法 | |
| HK1230718A (en) | Method for the detection of a binding partner of a multispecific binder | |
| HK1230718A1 (en) | Method for the detection of a binding partner of a multispecific binder | |
| HK1202921B (en) | Method for the detection of a binding partner of a multispecific binder | |
| HK40061170A (en) | Interference-suppressed pharmacokinetic immunoassay | |
| HK1201920B (en) | Method for the detection of free binding partner of a multispecific binder | |
| HK1208731B (en) | Method for the detection of a multispecific binder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1230718 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |